SmartTRAK interviews Arthrosurface CEO Steve Ek about the Company’s newest shoulder system, the OVOMotion, and what differentiates it from other current and emerging shoulder systems

The orthopedic industry has sharpened its focus on value-based care. Health care providers are looking for technologies that maximize care, reduce costs and increase efficiencies, while patients are seeking affordable treatment options that will restore their function and improve their quality of life.

At the 2019 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, Arthrosurface CEO Steve Ek, Dr. Greg Nicholson, Rush University Medical Center, and Dr. Anthony Miniaci, Cleveland Clinic, discussed the Company’s newest shoulder implant system, the OVOMotion stemless shoulder, and its value proposition for both health care providers and patients in an interview with SmartTRAK.

(This is Part 2 of SmartTRAK’s interview with Arthrosurface. Be sure to see Part 1 - "Arthrosurface Takes Aim at Patellofemoral Pain" - in which Arthrosurface discusses their new patellofemoral joint implant, the Wave Kahuna.)

The SmartTRAK analyst team is expanding and we are looking for an experienced and motivated individual who would like to manage one or more of our Advanced Wound Care modules, with a focus on the European markets. As you know, all of our SmartTRAK analysts are former marketing, business development or competitive intelligence professionals with one of the major medical device manufacturers and, in fact, most have come to us via recommendations from our subscribers. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add to the SmartTRAK platform.

Learn More and Apply
 

Intraoperative neuromonitoring could be a game changer in the field of SCS by elucidating the MOA for current and emerging SCS waveforms and stimulation patterns. But will it improve outcomes? To find out more, SmartTRAK interviewed Steven Falowski, MD at NANS 2019.

Steven Falowski, MD, Secretary of the Board for the North American Neuromodulation Society (NANS), discusses the latest research on the use of intraoperative neuromonitoring during spinal cord stimulation (SCS) in an interview with SmartTRAK at the NANS 22nd annual meeting held Jan. 17-20, 2019 in Las Vegas.

Historically, pain specialists have always placed spinal cord stimulators in awake patients for safety reasons and to confirm the therapy is adequately covering painful areas. However, Dr. Falowski says there’s been a paradigm shift where both pain physicians and surgeons alike are now using intraoperative neuromonitoring to place SCS systems for both percutaneous electrodes and paddle leads in asleep patients to more accurately localize the spinal cord midline and to improve intraoperative electrode placement and pain coverage... 

Revenues down again, competitive pricing pressures remain, market is under FDA scrutiny

After a sluggish start of the year, the US Joint Fluid market gained steam during the quarter as demand and volumes picked up in several market segments in spite of intense competitive pricing pressures. Revenues were within SmartTRAK’s projected range with a marginal decline of -0.3% YoY according to the recently published SmartTRAK Financial Dashboard.

For Q119, the 3-injection segment accounted for 44.6%  of the US Joint Fluid market, followed by single-injection products at 41.5%, the 5-injection segment at 12.9% and rounding up the market with the 2-injection segment at 1.1%, according to SmartTRAK Financial Dashboard results. The single-injection segment showed good recovery from last year driven by increased adoption of newer products and/or sales expansion measures by some suppliers. The 3-injection segment was down in the low single digits during Q119 owing to continued and fierce pricing competition. The 5-injection segment showed no reprieve from its downward trend, declining...

Among the many topics covered in the Q119 US Joint Fluid Market Recap are:

In an interview with SmartTRAK, Robert Levy, MD, president of the International Neuromodulation Society (INS), provides a preview of the research, emerging technologies, and trends in neuromodulation that will be at the INS 2019 14th World Congress to be held May 23-30, 2019 in Sydney, Australia. 

The meeting will highlight several important topics, including the use of neurostimulation to reduce opioid use, closed-loop neurostimulation, and advances in non-invasive brain stimulation, including for the treatment of post-traumatic stress disorder, depression, and for enhancing memory and learning.

In terms of research, Dr. Levy said Sam Eldabe, MD of the United Kingdom will provide a critical evaluation of clinical trials in neuromodulation. Researchers will also present the latest insight into mechanism of action, new data on neurostimulation for cardiac ischemia, as well as research on use of deep brain stimulation (DBS) for obesity, eating disorders and addiction. Researchers will also present important pivotal trial results, including: the Evoke Study (Saluda Medical), evaluating closed-loop spinal cord stimulation (SCS); the SURF study (Stimwave Technologies), comparing different wireless SCS frequencies and waveforms; and the ReActiv8 trial (Mainstay Medical), evaluating the use of a restorative neurostimulation system for nocioceptive chronic low back pain. 

On the technology front, the INS’s Innovation Day will highlight disruptive innovations in neuromodulation, and will feature panel discussions and presentations by researchers and major shareholders from early stage start-ups, middle-stage start-ups and well-established companies.

To find out more about the INS World Congress, click on the following video to listen to SmartTRAK’s interview with Dr. Levy recorded via phone from his office in Florida. A transcript of the interview is also provided below.

SmartTRAK Interviews Arthrosurface CEO Steve Ek about new WaveKahuna PFJ Implant

Arthrosurface hopes to expand the market for joint arthroplasty with a novel patellofemoral arthroplasty implant and five-year data demonstrating long-term clinical benefits for treating patients with patellofemoral pain earlier in the treatment continuum, with evidence suggesting that it halts the progression of osteoarthritis (OA).

Today, many of these patients fall into a treatment gap. As much as 22% of the US population could be suffering from patellofemoral pain, according to a recent analysis of data from 23 studies. PLoS One Many orthopedic surgeons remain unconvinced that surgical management is of long-term benefit. Instead they choose to manage these patients with conservative treatment until they become candidates for joint replacement.

To find out more about the Company’s new patellofemoral arthroplasty implant, the WaveKahuna, and how it can address surgeon concerns about long-term clinical benefits, SmartTRAK interviewed Arthrosurface CEO Steve Ek, and Gregory Nicholson, MD, Rush University Medical Center at the 2019 American Academy of Orthopaedic Surgeon’s (AAOS) Annual Meeting held March 12-16 in Las Vegas, NV.

Beautiful Gothenburg, Sweden is hosting EWMA 2019 - the European Wound Management Association conference, on June 5-9.

Gothenburg, Sweden's second largest city after Stockholm, located on the coast in southwestern Sweden, is considered "the quintessential 'second city': understatedly hip and unexpectedly vibrant with neoclassical architecture lining its tram-rattled streets, locals sunning themselves beside canals, and always an interesting cultural or social event going on."

Here are some of SmartTRAK's top things to do when taking a break from the conference. And we know what we're talking about - SmartTRAK's Senior Analyst, Advanced Wound Care, Lennart Stadler lives there!

IRVINE, CALIF. (PRWEB) MAY 13, 2019

BioMedGPS is excited to host its subscribers and guests on Tuesday, June 4th, at a very special Pre-EWMA 2019 event at Gothenburg’s Universeum Aquarium.

SmartTRAK will be hosting an exclusive Private Event Pre-EWMA at Gothenburg’s Universeum Aquarium. Guests will be treated to an aquarium tour, dinner and briefing on the latest Trends, Opportunities and Innovations in Advanced Wound Care.

SmartTRAK’s Advanced Wound Care Experts will serve as panelists. Susan Paquette - SmartTRAK VP & General Manager, Wound - will be providing overall insights on the wound market and Lennart Stadler - SmartTRAK Senior Analyst, Advanced Wound Care - will be presenting data on important trends and innovations.

SmartTRAK, the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies, was cited as a source in 3M's presentation "3M to Acquire Acelity Inc." published on May 2.

#SAWC2019 in San Antonio is fantastic! So many things to do and see. Stay tuned for articles from SmartTRAK with updates and highlights. In the meantime, a few photos!